<p><strong>Skeletal muscle effects (e.g., myopathy and rhabdomyolysis)</strong>: Risks increase with use of 40 mg dose, advanced age (&gt;65 year), hypothyroidism, renal impairment and combination use with cyclosporine, lopinavir/ritonavir, atazanavir/ritonavir or certain other lipid-lowering drugs. Patients should be advised to promptly report unexplained muscle pain, tenderness or weakness. Rosuvastatin can be discontinued if signs or symptoms appear.<br />
<br />
<strong>Liver enzyme abnormalities and monitoring</strong>: Persistent elevations in hepatic transaminases can occur.<br />
<br />
Liver enzymes should be monitored before and during treatment</p>